Trial Profile
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor, Idelalisib (GS-1101), in IgM-Associated AL Amyloid
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 15 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 03 Nov 2015 New trial record